GLPG 2737
Alternative Names: ABBV 2737; G 1117337; GLPG-2737Latest Information Update: 10 May 2026
At a glance
- Originator Cystic Fibrosis Foundation Therapeutics; Galapagos NV
- Class Antifibrotics; Small molecules
- Mechanism of Action Cystic fibrosis transmembrane conductance regulator inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Autosomal dominant polycystic kidney disease; Cystic fibrosis
Most Recent Events
- 08 May 2026 Galapagos NV is now called Lakefront Biotherapeutics
- 22 May 2023 Discontinued - Phase-I for Cystic fibrosis (Combination therapy) in Sweden, Serbia, Netherlands, Greece, Belgium, Bulgaria, United Kingdom (PO), prior to May 2023
- 22 May 2023 Discontinued - Phase-I for Cystic fibrosis (Combination therapy, In volunteers) in Belgium (PO), prior to May 2023